ADME Studies: Market Size & Forecast 2026

The global ADME studies market sits at approximately USD 5.8 billion in 2025 (base year), structured as a high-specialisation CRO service category anchored in GLP-regulated preclinical and early-clinical drug development. The 2026 price benchmark for a standard in-vivo rat PK study with bioanalytical support runs at roughly USD 8,500 per study [Claight estimate: standard reference SKU build from CRO pricing norms], with regional variation from USD 4,500 per study in Asia to USD 7,800 per study in the US and EUR 7,200 per study in Europe [Claight estimate: industry pricing reports, Q2 2026]. A 7.5% CAGR through 2032 reflects the dual engine of small-molecule pipeline complexity and biopharma large-molecule expansion, though the consensus sits closer to 8-9% across third-party aggregators, which we read as aggressive given mature-market discipline in pharma R&D spend. > **Analyst Take.** T

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.